– PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial’s primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) ...

Myocardial ischemia, a condition characterized by inadequate blood supply to the heart muscle, affects millions of people worldwide. While the focus of treatment has traditionally been on opening ...

Cardurion Pharmaceuticals has completed a $260 million Series B financing, with proceeds intended to advance its pipeline of cardiovascular drugs, as well as acquire additional therapeutic assets ...